A new COVID-19 medication has been approved in Abu Dhabi for the treatment of mild to moderate cases and those who have had direct contact with a patient.
The emirate's Department of Health (DoH) has partnered with Swiss healthcare company Roche to provide casirivimab and imdevimab to certain categories of patients.
The antibody combination has already been approved in the European Union and Japan, and conditionally approved in the UK and Australia.
It is also authorised for emergency use in the United States, India, Switzerland and Canada, and is recommended by the World Health Organisation (WHO).
.@DoHSocial has partnered with Swiss healthcare company @Roche to provide a new Covid-19 medication, approved for emergency use, to treat mild to moderate Covid-19 cases and those who have had direct contact with a positive case.
— مكتب أبوظبي الإعلامي (@ADMediaOffice) December 1, 2021
Read more: https://t.co/vGQXyUvhGB pic.twitter.com/Yj9JxVgemP


GCAA completes passenger transfers after flydubai Tel Aviv suspension
Dubai honours outstanding educators with Golden Visas
UAE condemns Israeli excavation, fortification works in Syrian territory
UAE-Jordan partnership advances with major railway project
UAE leaders mark World Teachers' Day with special message for educators
H.H. Sheikh Hamdan reviews defence development, readiness plans
Abu Dhabi Crown Prince arrives in Aqaba on working visit
UAE foils 14 bids to smuggle 300kg of narcotics in under 2 months
